pyridoxamine has been researched along with pimagedine in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (10.34) | 18.2507 |
| 2000's | 17 (58.62) | 29.6817 |
| 2010's | 9 (31.03) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Audic, N; Ermolenko, L; Franck, G; Garcia-Alvarez, MC; Martin, MT; Nhiri, N; Potier, P; Sasaki, NA; Wang, Q | 1 |
| Booth, AA; Hudson, BG; Khalifah, RG | 1 |
| Booth, AA; Hudson, BG; Khalifah, RG; Todd, P | 1 |
| Baynes, JW; Hudson, BG; Khalifah, RG | 1 |
| Baynes, JW; Thorpe, SR | 1 |
| Green, MH; Ide, H; Kaji, K; Kinae, N; Lowe, JE; Ohta, T; Okitsu, A; Shimoi, K; Terato, H | 1 |
| Baynes, JW; Price, DL; Rhett, PM; Thorpe, SR | 1 |
| Alderson, NL; Arrington, DD; Basgen, JM; Baynes, JW; Beattie, RJ; Degenhardt, TP; Steffes, MW; Thorpe, SR | 1 |
| Burcham, PC; Fontaine, FR; Kaminskas, LM; Petersen, DR; Pyke, SM | 1 |
| Jakus, V; Rietbrock, N | 1 |
| Ishikawa, N; Kurokawa, K; Miyata, T | 1 |
| Williams, ME | 1 |
| Imaizumi, T; Yamagishi, S | 1 |
| Baynes, JW; Cooper, ME; Thomas, MC; Thorpe, SR | 1 |
| Cooper, ME; Coughlan, MT; Forbes, JM | 1 |
| Cameron, NE; Cotter, MA; Gibson, TM; Nangle, MR | 1 |
| Chen, Y; Khalifah, RG; Wassenberg, JJ | 1 |
| Grahovac, G; Kalluri, R; Sugimoto, H; Zeisberg, M | 1 |
| Adrover, M; Donoso, J; Frau, J; Muñoz, F; Vilanova, B | 1 |
| Barter, PJ; Brown, BE; Davies, MJ; Nobécourt, E; Rye, KA; Yadav, S; Zeng, J | 1 |
| Koh, G; Lee, DH; Woo, JT | 1 |
| Bolton, WK; Turgut, F | 1 |
| Dedina, L; Mehta, R; O'Brien, PJ | 1 |
| Bloemen, JG; Buurman, WA; Dejong, CH; Driessen, A; Gaens, KH; Greve, JW; Hofker, MH; Niessen, PM; Rensen, SS; Schalkwijk, CG; Stehouwer, CD; Wolfs, MG | 1 |
| Tomino, Y | 1 |
| Casasnovas, R; Donoso, J; Fernández, D; Frau, J; Muñoz, F; Ortega-Castro, J | 1 |
| Engelen, L; Schalkwijk, CG; Stehouwer, CD | 1 |
| Bidasee, KR; Kutty, S; Moore, CJ; Nagai, R; Shao, CH; Singh, J | 1 |
| Aldini, G; Carini, M; Casali, G; Colzani, M; De Maddis, D; Vistoli, G | 1 |
14 review(s) available for pyridoxamine and pimagedine
| Article | Year |
|---|---|
Amadorins: novel post-Amadori inhibitors of advanced glycation reactions.
Topics: Diabetes Mellitus; Drug Design; Glycation End Products, Advanced; Guanidines; Pyridoxamine; Schiff Bases | 1999 |
Glycoxidation and lipoxidation in atherogenesis.
Topics: Aldehydes; Animals; Antioxidants; Arteriosclerosis; Carbohydrate Metabolism; Endothelium, Vascular; Glycation End Products, Advanced; Guanidines; Humans; Lipid Metabolism; Lipid Peroxidation; Oxidation-Reduction; Pyridoxamine | 2000 |
Aldehyde-sequestering drugs: tools for studying protein damage by lipid peroxidation products.
Topics: Acrolein; Aldehydes; Animals; Carnosine; Guanidines; Humans; Hydralazine; Lipid Peroxidation; Oxidation-Reduction; Proteins; Pyridoxamine | 2002 |
Advanced glycation end-products and the progress of diabetic vascular complications.
Topics: Arteriosclerosis; Diabetes Complications; Diabetes Mellitus; Glycation End Products, Advanced; Glycosylation; Guanidines; Humans; Hyperglycemia; Oxidative Stress; Peptides; Pyridoxamine; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Vascular Diseases | 2004 |
[Carbonyl stress inhibitor towards new therapeutic interventions in diabetic nephropathy].
Topics: Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Diabetes Mellitus; Diabetic Nephropathies; Glycation End Products, Advanced; Guanidines; Humans; Hydralazine; Hydrazines; Imidazoles; Olmesartan Medoxomil; Oxidative Stress; Pyridoxamine; Tetrazoles | 2004 |
Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease.
Topics: Diabetic Nephropathies; Enzyme Inhibitors; Glycation End Products, Advanced; Guanidines; Humans; Models, Biological; Pyridoxamine | 2004 |
[Progress on the drug therapy for diabetic microangiopathies: AGE inhibitors].
Topics: Animals; Clinical Trials as Topic; Depression, Chemical; Diabetic Angiopathies; Glycation End Products, Advanced; Guanidines; Humans; Oxidative Stress; Pyridoxamine; Thiadiazoles; Thiamine; Thiazoles; Thiazolidines | 2005 |
The role of AGEs and AGE inhibitors in diabetic cardiovascular disease.
Topics: Animals; Diabetic Angiopathies; Glycation End Products, Advanced; Guanidines; Humans; Ligands; Oxidative Stress; Pyridoxamine; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Renin-Angiotensin System; Thiamine | 2005 |
Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?
Topics: Animals; Diabetic Nephropathies; Disease Models, Animal; Glycation End Products, Advanced; Guanidines; Humans; Pyridoxamine; Renin-Angiotensin System; Thiadiazoles; Thiazolidines | 2005 |
Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Neuropathies; Glycation End Products, Advanced; Guanidines; Lipid Peroxidation; Pyridoxamine | 2005 |
Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design.
Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Drug Design; Glycation End Products, Advanced; Guanidines; Humans; Models, Biological; Pyridoxamine | 2005 |
Potential new therapeutic agents for diabetic kidney disease.
Topics: Amides; Animals; Clinical Trials as Topic; Connective Tissue Growth Factor; Diabetic Nephropathies; Disease Progression; Endothelin Receptor Antagonists; Glycation End Products, Advanced; Glycosaminoglycans; Guanidines; Humans; Hydrazines; Kidney; NADPH Oxidases; Nitric Oxide Synthase; Pentoxifylline; Phosphodiesterase Inhibitors; Pyridines; Pyridoxamine; Pyrimidines; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A; Vitamin B Complex | 2010 |
Mechanisms and interventions in peritoneal fibrosis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Epithelial Cells; Epithelium; Glycation End Products, Advanced; Guanidines; Humans; Kidney Failure, Chronic; ortho-Aminobenzoates; Peritoneal Dialysis; Peritoneal Fibrosis; Peritoneum; Phenyl Ethers; Pyridoxamine; Renin-Angiotensin System; Vascular Endothelial Growth Factor A | 2012 |
Current therapeutic interventions in the glycation pathway: evidence from clinical studies.
Topics: Animals; Atherosclerosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Enzyme Inhibitors; Evidence-Based Medicine; Female; Glycation End Products, Advanced; Guanidines; Humans; Hyperglycemia; Male; Pyridoxamine; Thiamine; Thiazoles; Treatment Outcome | 2013 |
15 other study(ies) available for pyridoxamine and pimagedine
| Article | Year |
|---|---|
N-Terminal 2,3-diaminopropionic acid (Dap) peptides as efficient methylglyoxal scavengers to inhibit advanced glycation endproduct (AGE) formation.
Topics: beta-Alanine; Chromatography, High Pressure Liquid; Electrophoresis, Polyacrylamide Gel; Glycation End Products, Advanced; Magnetic Resonance Spectroscopy; Peptides; Pyruvaldehyde | 2009 |
Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine.
Topics: Animals; Antigens; Cattle; Diabetes Complications; Diabetes Mellitus; Enzyme Inhibitors; Glycation End Products, Advanced; Glycosylation; Guanidines; Humans; In Vitro Techniques; Male; Methemoglobin; Pyridoxamine; Rabbits; Ribonuclease, Pancreatic; Serum Albumin, Bovine; Thiamine Pyrophosphate | 1996 |
In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways.
Topics: Animals; Bacterial Proteins; Carrier Proteins; Cattle; Enzyme-Linked Immunosorbent Assay; Glycation End Products, Advanced; Guanidines; Hemoglobins; Intracellular Signaling Peptides and Proteins; Kinetics; Pyridoxamine; Ribonuclease, Pancreatic; Ribose; Serum Albumin; Thiamine Pyrophosphate | 1997 |
Oxidative DNA damage induced by high glucose and its suppression in human umbilical vein endothelial cells.
Topics: Binding Sites; Cells, Cultured; Comet Assay; DNA; DNA Damage; DNA-Formamidopyrimidine Glycosylase; Dose-Response Relationship, Drug; Endothelium, Vascular; Flow Cytometry; Glucose; Guanidines; Humans; N-Glycosyl Hydrolases; Oxidation-Reduction; Pyridoxamine; Reactive Oxygen Species; Umbilical Veins | 2001 |
Chelating activity of advanced glycation end-product inhibitors.
Topics: Amines; Antioxidants; Ascorbic Acid; Bromides; Chelating Agents; Copper; Diabetes Complications; Diabetes Mellitus; Enzyme Inhibitors; Glycation End Products, Advanced; Guanidines; Oxidation-Reduction; Pyridoxamine; Serum Albumin, Bovine | 2001 |
Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.
Topics: Animals; Collagen; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Progression; Female; Glycation End Products, Advanced; Guanidines; Hyperlipidemias; Lipid Metabolism; Oxidation-Reduction; Pyridoxamine; Rats; Rats, Sprague-Dawley | 2002 |
Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors.
Topics: Animals; Bone Morphogenetic Protein 7; Bone Morphogenetic Proteins; Diabetic Nephropathies; Disease Models, Animal; Fibrosis; Glycation End Products, Advanced; Guanidines; Humans; Kidney; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Pyridoxamine; Remission Induction; Renal Agents | 2007 |
The pyridoxamine action on Amadori compounds: A reexamination of its scavenging capacity and chelating effect.
Topics: Amino Acids; Ascorbic Acid; Chelating Agents; Chromatography, High Pressure Liquid; Free Radical Scavengers; Fructose; Glucose; Glycation End Products, Advanced; Glycosylation; Guanidines; Kinetics; Ligands; Magnetic Resonance Spectroscopy; Molecular Structure; Organometallic Compounds; Oxidation-Reduction; Pyridoxamine; Schiff Bases; Stereoisomerism; Time Factors; Tryptophan; Zinc | 2008 |
Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I.
Topics: Apolipoprotein A-I; Arginine; Cross-Linking Reagents; Glycosylation; Guanidines; Humans; Lipoproteins, HDL; Lysine; Metformin; Phosphatidylcholine-Sterol O-Acyltransferase; Pyridoxamine; Pyruvaldehyde; Thiazoles; Tryptophan | 2008 |
2-Deoxy-D-ribose induces cellular damage by increasing oxidative stress and protein glycation in a pancreatic beta-cell line.
Topics: Annexin A5; Apoptosis; Cell Line; Cell Survival; Deoxyribose; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flow Cytometry; Glycation End Products, Advanced; Glycoproteins; Guanidines; Humans; Insulin-Secreting Cells; Oxidative Stress; Pentetic Acid; Protein Carbonylation; Pyridoxamine; Reactive Oxygen Species | 2010 |
Rescuing hepatocytes from iron-catalyzed oxidative stress using vitamins B1 and B6.
Topics: Animals; Antioxidants; Butylated Hydroxyanisole; Cell Survival; Cells, Cultured; Comet Assay; Cytoprotection; Deoxyribose; DNA Damage; Guanidines; Hepatocytes; Iron; Lipid Peroxidation; Male; Mitochondria; Oxidative Stress; Phenanthrolines; Protein Carbonylation; Pyridoxamine; Quercetin; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Thiamine; Vitamin B 6; Vitamin B Complex | 2011 |
Endogenous formation of Nε-(carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis.
Topics: Aged; Biomarkers; Biopsy; Cytokines; Enzyme Inhibitors; Fatty Liver; Female; Gene Expression; Guanidines; Hep G2 Cells; Hepatocytes; Humans; In Vitro Techniques; Liver; Lysine; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Pyridoxamine; Vitamin B Complex | 2012 |
High- and low-spin Fe(III) complexes of various AGE inhibitors.
Topics: Ascorbic Acid; Coordination Complexes; Edetic Acid; Ferric Compounds; Glycation End Products, Advanced; Guanidines; Kinetics; Ligands; Molecular Structure; Propionates; Pyridoxamine; Quantum Theory; Quinolines; Thermodynamics | 2012 |
Malondialdehyde and 4-hydroxynonenal adducts are not formed on cardiac ryanodine receptor (RyR2) and sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA2) in diabetes.
Topics: Aldehydes; Animals; Arginine; Calcium; Cyclic N-Oxides; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Echocardiography; Guanidines; Lysine; Male; Malondialdehyde; Myocytes, Cardiac; Norleucine; Protein Carbonylation; Pyridoxamine; Pyrroles; Rats; Rats, Sprague-Dawley; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Spin Labels | 2013 |
Reactivity, Selectivity, and Reaction Mechanisms of Aminoguanidine, Hydralazine, Pyridoxamine, and Carnosine as Sequestering Agents of Reactive Carbonyl Species: A Comparative Study.
Topics: Aldehydes; Carnosine; Dose-Response Relationship, Drug; Glyoxal; Guanidines; Humans; Hydralazine; Malondialdehyde; Molecular Structure; Pyridoxamine; Pyruvaldehyde; Sequestering Agents; Structure-Activity Relationship | 2016 |